Tobramycin treatment of pseudomonas aeruginosa infections in cystic fibrosis.

Tobramycin treatment of chronic pulmonary infections caused by Pseudomonas aeruginosa in 13 
children with cystic fibrosis was evaluated. Initially the patients received the 
recommended dose of 125 mg/m2/24 hours; the dose was then increased 
to 250 mg/m2/24 hours (approximately 10 mg/kg/24 hours). This higher dosage 
was administered intramuscularly to 9 patients. Eight of these received additional 
therapy with an aerosol containing tobramycin. With this therapy it was 
possible to eradicate Ps. aeruginosa from the respiratory tract in 5 
of the patients. After discontinuing therapy Ps. aeruginosa re-occurred in all 
patients within one month. All patients showed a clinical improvement in 
relation to therapy. No toxic or allergic side effects were observed. 
